Literature DB >> 24454106

(R)-(-)-Quinuclidin-3-ol.

Yoann Rousselin1, Alexandre Clavel2, Isabelle Bonnaventure2.   

Abstract

The structure of the title compound [alternatively called (R)-(-)-1-aza-bicyclo-[2.2.2]octan-3-ol], C7H13NO, at 100 K has hexa-gonal (P61) symmetry. The structure shows a twist along the C-N pseudo-threefold axis. In the crystal, mol-ecules are linked via O-H⋯N hydrogen bonds, forming infinite chains along the c-axis direction. The crystal studied was twinned by merohedry (twin law: 010, 100, 00-1; population: 0.925:0.075).

Entities:  

Year:  2013        PMID: 24454106      PMCID: PMC3884330          DOI: 10.1107/S1600536813026998

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

The title compound is a key building block for the syntheses of muscarinic receptor ligands, including solifenacin (Naito et al., 2005 ▶), revatropate (Alabaster, 1997 ▶) and talsaclidine (Leusch et al., 2000 ▶). For properties of the title compound, see: Bosak et al. (2005 ▶); Carroll et al. (1991 ▶); Frackenpohl & Hoffmann (2000 ▶); Day & Motherwell (2006 ▶); Malone & Armstrong (2006 ▶); Siczek & Lis (2008 ▶); Sterling et al. (1988 ▶). For puckering parameters, see: Cremer & Pople (1975 ▶); For absolute configuration, see: Flack (1983 ▶); The twin law was determined using TwinRotMat implemented in PLATON (Spek, 2009 ▶).

Experimental

Crystal data

C7H13NO M = 127.18 Hexagonal, a = 6.2076 (3) Å c = 29.8731 (13) Å V = 996.91 (11) Å3 Z = 6 Cu Kα1 radiation μ = 0.67 mm−1 T = 100 K 0.58 × 0.44 × 0.32 mm

Data collection

Bruker D8 VENTURE diffractometer Absorption correction: numerical (SADABS; Bruker, 2012 ▶) T min = 0.58, T max = 0.74 15447 measured reflections 1240 independent reflections 1240 reflections with I > 2σ(I) R int = 0.026

Refinement

R[F 2 > 2σ(F 2)] = 0.023 wR(F 2) = 0.064 S = 1.15 1240 reflections 85 parameters 1 restraint H-atom parameters constrained Δρmax = 0.23 e Å−3 Δρmin = −0.12 e Å−3 Absolute structure: Parsons & Flack (2004 ▶). Absolute structure parameter: 0.01 (4) Data collection: APEX2 (Bruker, 2012 ▶); cell refinement: SAINT (Bruker, 2012 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: OLEX2 (Dolomanov et al., 2009 ▶); software used to prepare material for publication: OLEX2. Crystal structure: contains datablock(s) I. DOI: 10.1107/S1600536813026998/bg2517sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536813026998/bg2517Isup2.hkl Click here for additional data file. Supplementary material file. DOI: 10.1107/S1600536813026998/bg2517Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C7H13NODx = 1.271 Mg m3
Mr = 127.18Melting point: 492(2) K
Hexagonal, P61Cu Kα1 radiation, λ = 1.54178 Å
a = 6.2076 (3) ŵ = 0.67 mm1
c = 29.8731 (13) ÅT = 100 K
V = 996.91 (11) Å3Prism, clear light colourless
Z = 60.58 × 0.44 × 0.32 mm
F(000) = 420
Bruker D8 VENTURE diffractometer1240 independent reflections
Radiation source: sealed X-ray tube, high brilliance microfocus sealed tube, Cu1240 reflections with I > 2σ(I)
Graphite monochromatorRint = 0.026
Detector resolution: 1024 x 1024 pixels mm-1θmax = 69.2°, θmin = 4.4°
φ and ω scansh = −7→7
Absorption correction: numerical (SADABS; Bruker, 2012)k = −7→7
Tmin = 0.58, Tmax = 0.74l = −34→35
15447 measured reflections
Refinement on F2Hydrogen site location: inferred from neighbouring sites
Least-squares matrix: fullH-atom parameters constrained
R[F2 > 2σ(F2)] = 0.023w = 1/[σ2(Fo2) + (0.0394P)2 + 0.1183P] where P = (Fo2 + 2Fc2)/3
wR(F2) = 0.064(Δ/σ)max < 0.001
S = 1.15Δρmax = 0.23 e Å3
1240 reflectionsΔρmin = −0.12 e Å3
85 parametersExtinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4
1 restraintExtinction coefficient: 0.0156 (15)
0 constraintsAbsolute structure: Parsons & Flack (2004).
Primary atom site location: structure-invariant direct methodsAbsolute structure parameter: 0.01 (4)
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refined as a 2-component twin.
xyzUiso*/Ueq
O1−0.1928 (2)0.4528 (2)0.48963 (4)0.0175 (3)
H1−0.22530.42640.46220.026*
N10.3057 (3)0.6832 (3)0.56404 (5)0.0157 (4)
C20.5095 (3)0.8018 (3)0.48879 (6)0.0166 (4)
H2A0.53250.95000.47220.020*
H2B0.63780.76250.47860.020*
C40.0565 (3)0.6495 (3)0.49520 (5)0.0149 (4)
H40.08120.79990.47850.018*
C10.5354 (4)0.8550 (4)0.53973 (6)0.0208 (4)
H1A0.67520.83800.55150.025*
H1B0.57441.02830.54500.025*
C70.2139 (3)0.3542 (3)0.50634 (5)0.0159 (4)
H7A0.33690.30670.49660.019*
H7B0.04500.21110.50130.019*
C50.0986 (4)0.7091 (4)0.54597 (5)0.0188 (4)
H5A0.13400.88140.55100.023*
H5B−0.05570.59560.56240.023*
C30.2487 (3)0.5801 (3)0.47977 (6)0.0141 (4)
H30.22790.54060.44710.017*
C60.2509 (4)0.4253 (4)0.55649 (6)0.0204 (4)
H6A0.09840.30950.57320.024*
H6B0.38970.40680.56840.024*
U11U22U33U12U13U23
O10.0134 (6)0.0222 (6)0.0150 (6)0.0076 (5)−0.0012 (4)−0.0004 (5)
N10.0176 (7)0.0155 (8)0.0128 (7)0.0074 (6)−0.0005 (6)−0.0014 (5)
C20.0149 (8)0.0186 (9)0.0145 (8)0.0069 (7)0.0009 (7)0.0010 (6)
C40.0150 (8)0.0161 (8)0.0138 (8)0.0079 (7)−0.0002 (6)0.0006 (7)
C10.0176 (9)0.0215 (9)0.0164 (9)0.0045 (8)−0.0020 (6)−0.0034 (7)
C70.0150 (8)0.0151 (8)0.0177 (8)0.0077 (7)−0.0012 (6)−0.0028 (7)
C50.0207 (9)0.0237 (9)0.0153 (8)0.0135 (8)−0.0006 (7)−0.0042 (7)
C30.0135 (8)0.0158 (8)0.0124 (8)0.0068 (7)−0.0011 (6)−0.0024 (7)
C60.0292 (9)0.0186 (9)0.0159 (9)0.0139 (8)−0.0003 (8)0.0013 (7)
O1—H10.8400C1—H1A0.9900
O1—C41.423 (2)C1—H1B0.9900
N1—C11.475 (2)C7—H7A0.9900
N1—C51.475 (2)C7—H7B0.9900
N1—C61.479 (2)C7—C31.530 (2)
C2—H2A0.9900C7—C61.546 (2)
C2—H2B0.9900C5—H5A0.9900
C2—C11.548 (2)C5—H5B0.9900
C2—C31.536 (2)C3—H31.0000
C4—H41.0000C6—H6A0.9900
C4—C51.552 (2)C6—H6B0.9900
C4—C31.528 (2)
C4—O1—H1109.5C3—C7—H7A110.1
C1—N1—C6108.86 (15)C3—C7—H7B110.1
C5—N1—C1108.73 (14)C3—C7—C6107.96 (13)
C5—N1—C6108.72 (14)C6—C7—H7A110.1
H2A—C2—H2B108.4C6—C7—H7B110.1
C1—C2—H2A110.0N1—C5—C4112.56 (14)
C1—C2—H2B110.0N1—C5—H5A109.1
C3—C2—H2A110.0N1—C5—H5B109.1
C3—C2—H2B110.0C4—C5—H5A109.1
C3—C2—C1108.29 (15)C4—C5—H5B109.1
O1—C4—H4109.6H5A—C5—H5B107.8
O1—C4—C5107.46 (13)C2—C3—H3109.9
O1—C4—C3112.96 (14)C4—C3—C2108.41 (14)
C5—C4—H4109.6C4—C3—C7109.25 (14)
C3—C4—H4109.6C4—C3—H3109.9
C3—C4—C5107.45 (13)C7—C3—C2109.45 (14)
N1—C1—C2111.72 (14)C7—C3—H3109.9
N1—C1—H1A109.3N1—C6—C7112.19 (14)
N1—C1—H1B109.3N1—C6—H6A109.2
C2—C1—H1A109.3N1—C6—H6B109.2
C2—C1—H1B109.3C7—C6—H6A109.2
H1A—C1—H1B107.9C7—C6—H6B109.2
H7A—C7—H7B108.4H6A—C6—H6B107.9
O1—C4—C5—N1122.04 (17)C5—C4—C3—C2−59.75 (17)
O1—C4—C3—C2−178.09 (13)C5—C4—C3—C759.46 (17)
O1—C4—C3—C7−58.88 (17)C3—C2—C1—N1−0.9 (2)
C1—N1—C5—C459.38 (18)C3—C4—C5—N10.20 (19)
C1—N1—C6—C7−59.78 (19)C3—C7—C6—N10.4 (2)
C1—C2—C3—C460.54 (19)C6—N1—C1—C259.72 (19)
C1—C2—C3—C7−58.55 (18)C6—N1—C5—C4−59.01 (19)
C5—N1—C1—C2−58.6 (2)C6—C7—C3—C258.56 (18)
C5—N1—C6—C758.53 (19)C6—C7—C3—C4−60.01 (17)
D—H···AD—HH···AD···AD—H···A
O1—H1···N1i0.842.002.8366 (19)176
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯A D—HH⋯A DA D—H⋯A
O1—H1⋯N1i 0.842.002.8366 (19)176

Symmetry code: (i) .

  9 in total

1.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

2.  In vivo protection against soman toxicity by known inhibitors of acetylcholine synthesis in vitro.

Authors:  G H Sterling; P H Doukas; R J Sheldon; J J O'Neill
Journal:  Biochem Pharmacol       Date:  1988-02-01       Impact factor: 5.858

3.  Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.

Authors:  Yu Ko; Daniel C Malone; Edward P Armstrong
Journal:  Pharmacotherapy       Date:  2006-12       Impact factor: 4.705

Review 4.  Discovery & development of selective M3 antagonists for clinical use.

Authors:  V A Alabaster
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

5.  Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.

Authors:  Ryo Naito; Yasuhiro Yonetoku; Yoshinori Okamoto; Akira Toyoshima; Ken Ikeda; Makoto Takeuchi
Journal:  J Med Chem       Date:  2005-10-20       Impact factor: 7.446

6.  Synthesis of enantiopure 3-quinuclidinone analogues with three stereogenic centers: (1S,2R,4S)- and (1S,2S, 4S)-2-(Hydroxymethyl)-1-azabicyclo[2.2.2]octan-5-one and stereocontrol of nucleophilic addition to the carbonyl group.

Authors:  J Frackenpohl; H M Hoffmann
Journal:  J Org Chem       Date:  2000-06-30       Impact factor: 4.354

7.  Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man.

Authors:  A Leusch; W Tröger; A Greischel; W Roth
Journal:  Xenobiotica       Date:  2000-08       Impact factor: 1.908

8.  (R)-(-)-3-Hydroxy-quinuclidinium chloride.

Authors:  Miłosz Siczek; Tadeusz Lis
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-04-16

9.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.